Cell Free DNA 10ml Reduced Patient Risk Early Disease Detection Cancer

Orsin Medical Technology – Cell-Free DNA (cfDNA) Extraction & Analysis Solutions

1. Product Description

Orsin Medical Technology delivers high-efficiency, ultra-sensitive cfDNA extraction and detection products, designed for liquid biopsy, non-invasive prenatal testing (NIPT), cancer early screening, and transplant monitoring.

Key Advantages:

✔ Ultra-Low Input Compatibility – Reliable extraction even from minimal samples (e.g., 1mL plasma).

✔ High Recovery Rate & Minimal Fragmentation – Proprietary technology preserves short fragments (~150-200bp), ensuring optimal ctDNA/fetal DNA capture.

✔ Automation-Ready – Supports high-throughput processing for clinical and research applications.

✔ Multi-Platform Compatibility – Seamless integration with qPCR, ddPCR, NGS, and other downstream analyses. Applications: Cancer Monitoring – Dynamic tumor burden tracking & treatment response. NIPT – Safe, accurate fetal genetic screening. Transplant Rejection Surveillance – Donor-derived cfDNA (dd-cfDNA) detection. Purer cfDNA, Stronger Diagnostics —Orsin Medical Technology, Powering Precision Medicine.

2,Technical Specifications & Competitive Advantages

1.Core Performance Parameters

2. Key Differentiators vs Competitors

3. Downstream Compatibility

• NGS: <5% adapter dimers (vs 15-30% in standard kits)

• ddPCR: CV <3% for low-abundance mutations (0.1% VAF)

• Methylation Analysis: Preserves epigenetic signatures

4. Validation Data

• LoD: 0.01% mutant allele frequency (MAF) in 5ng cfDNA

• Reproducibility: 98% concordance in 500+ clinical samples

At Orsin Medical Technology, we combine cutting-edge innovation with clinical practicality to redefine liquid biopsy standards. Our cfDNA solutions are:
Validated – Rigorously tested in CAP/CLIA environments
Scalable – From research to high-volume clinical labs
Evolving – Continuous optimization for emerging biomarkers (e.g., fragmentomics, methylation patterns)
Partner with us to unlock the full potential of liquid biopsy.
Contact our technical team for assay validation protocols & application-specific protocols.